Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Positron Emission Tomography | Research article

Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines

Authors: Hendrik Dapper, Kilian Schiller, Stefan Münch, Jan C. Peeken, Kai Borm, Wolfgang Weber, Stephanie E. Combs

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

There are different contouring guidelines for the clinical target volume (CTV) in anal cancer (AC) which vary concerning recommendations for radiation margins in different anatomical regions, especially on inguinal site. PET imaging has become more important in primary staging of AC as a very sensitive method to detect lymph node (LN) metastases. Using PET imaging, we evaluated patterns of LN spread, and examined the differences of the respective contouring guidelines on the basis of our results.

Methods

We carried out a retrospective study of thirty-seven AC patients treated with chemoradiation (CRT) who underwent FDG-PET imaging for primary staging in our department between 2011 and 2018. Patients showing PET positive LN were included in this analysis. Using a color code, LN metastases of all patients were delineated on a template with “standard anatomy” and were divided indicating whether their location was in- or out-field of the standard CTV as recommended by the Radiation Therapy Oncology Group (RTOG), the Australasian Gastrointestinal Trials Group (AGITG) or the British National Guidance (BNG). Furthermore, a detailed analysis of the location of LN of the inguinal region was performed.

Results

Twenty-two out of thirty-seven AC patients with pre-treatment PET imaging had PET positive LN metastases, accumulating to a total of 154 LN. The most commonly affected anatomical region was inguinal (49 LN, 32%). All para-rectal, external/internal iliac, and pre-sacral LN were covered by the recommended CTVs of the three different guidelines. Of forty-nine involved inguinal LN, fourteen (29%), seven (14%) and five (10%) were situated outside of the recommended CTVs by RTOG, AGITG and BNG. Inguinal LN could be located up to 5.7 cm inferiorly to the femoral saphenous junction and 2.8 cm medial or laterally to the big femoral vessels.

Conclusion

Pelvis-related, various recommendations are largely consistent, and all LN are covered by the recommended CTVs. LN “misses” appear generally cranially (common iliac or para-aortic) or caudally (inguinal) to the recommended CTVs. The established guidelines differ significantly, particular regarding the inguinal region. Based on our results, we presented our suggestions for CTV definition of the inguinal region. LN involvement of a larger number of patients should be investigated to enable final recommendations.
Literature
1.
go back to reference Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914–21.CrossRef Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914–21.CrossRef
2.
go back to reference James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013;14:516–24.CrossRef James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013;14:516–24.CrossRef
3.
go back to reference Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010;116:4007–13.CrossRef Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010;116:4007–13.CrossRef
4.
go back to reference Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum. 2009;52:624–31.CrossRef Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum. 2009;52:624–31.CrossRef
5.
go back to reference Deans GT, McAleer JJ, Spence RA. Malignant anal tumors. Br J Surg. 1994;81:500–8.CrossRef Deans GT, McAleer JJ, Spence RA. Malignant anal tumors. Br J Surg. 1994;81:500–8.CrossRef
6.
go back to reference Gerard JP, Chapet O, Samiei F, et al. Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature. Cancer. 2001;92:77–84.CrossRef Gerard JP, Chapet O, Samiei F, et al. Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature. Cancer. 2001;92:77–84.CrossRef
7.
go back to reference Salati SA, Al Kadi A. Anal cancer - a review. Int J Health Sci (Qassim). 2012;6:206–30.CrossRef Salati SA, Al Kadi A. Anal cancer - a review. Int J Health Sci (Qassim). 2012;6:206–30.CrossRef
8.
go back to reference Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74:824–30.CrossRef Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74:824–30.CrossRef
9.
go back to reference Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The role of FDG-PET in the initial staging and response assessment of anal Cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22:3574–81.CrossRef Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The role of FDG-PET in the initial staging and response assessment of anal Cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22:3574–81.CrossRef
10.
go back to reference Lee NY, Lu JJ. Target volume delineation and field setup: a practical guide for conformal and intensity modulated radiation therapy. Berlin, Heidelberg: Springer; 2013.CrossRef Lee NY, Lu JJ. Target volume delineation and field setup: a practical guide for conformal and intensity modulated radiation therapy. Berlin, Heidelberg: Springer; 2013.CrossRef
11.
go back to reference Ng M, Leong T, Chander S, et al. Australasian gastrointestinal trials group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012;83:1455–62.CrossRef Ng M, Leong T, Chander S, et al. Australasian gastrointestinal trials group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012;83:1455–62.CrossRef
12.
go back to reference Muirhead R, Adams RA, Gilbert DC, Harrison M, Glynne-Jones R, Sebag-Montefiore D, Hawkins MA. NATIONAL GUIDANCE FOR IMRT IN ANAL NATIONAL GUIDANCE FOR IMRT IN ANAL CANCER: the CRUK/MRC oxford institute for radiation oncology, Oxford; School of Medicine, Cardiff University, Cardiff; Sussex Cancer Centre, Royal Sussex County Hospital, Brighton; Mount Vernon Hospital, Northwood; University of Leeds, St James Institute of Oncology, Leeds; 2016. http://analimrtguidance.co.uk/national-anal-imrt-guidance-v3.pdf. Accessed 8 Aug 2018. Muirhead R, Adams RA, Gilbert DC, Harrison M, Glynne-Jones R, Sebag-Montefiore D, Hawkins MA. NATIONAL GUIDANCE FOR IMRT IN ANAL NATIONAL GUIDANCE FOR IMRT IN ANAL CANCER: the CRUK/MRC oxford institute for radiation oncology, Oxford; School of Medicine, Cardiff University, Cardiff; Sussex Cancer Centre, Royal Sussex County Hospital, Brighton; Mount Vernon Hospital, Northwood; University of Leeds, St James Institute of Oncology, Leeds; 2016. http://​analimrtguidance​.​co.​uk/​national-anal-imrt-guidance-v3.​pdf. Accessed 8 Aug 2018.
13.
go back to reference Schiller K, Devecka M, Maurer T, et al. Impact of 68Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer. Radiat Oncol. 2018;13:36.CrossRef Schiller K, Devecka M, Maurer T, et al. Impact of 68Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer. Radiat Oncol. 2018;13:36.CrossRef
14.
go back to reference Teagle AR, Gilbert DC, Jones JR, Burkill GJ, McKinna F, Dizdarevic S. Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer. Nucl Med Commun. 2016;37:1038–45.CrossRef Teagle AR, Gilbert DC, Jones JR, Burkill GJ, McKinna F, Dizdarevic S. Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer. Nucl Med Commun. 2016;37:1038–45.CrossRef
15.
go back to reference Brierley J, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. Chichester, Hoboken: Wiley; 2017. Brierley J, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. Chichester, Hoboken: Wiley; 2017.
16.
go back to reference Aumüller G, Wolff W. Duale Reihe - Anatomie. 1st ed. Stuttgart: Thieme; 2007. Aumüller G, Wolff W. Duale Reihe - Anatomie. 1st ed. Stuttgart: Thieme; 2007.
17.
go back to reference Engstrom PF, Arnoletti JP, Benson AB, et al. NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Cancer Netw. 2010;8:106–20.CrossRef Engstrom PF, Arnoletti JP, Benson AB, et al. NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Cancer Netw. 2010;8:106–20.CrossRef
18.
go back to reference Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. J Natl Compr Cancer Netw. 2010;8:123–9.CrossRef Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. J Natl Compr Cancer Netw. 2010;8:123–9.CrossRef
19.
go back to reference Hodges JC, Das P, Eng C, et al. Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with Para-aortic nodal involvement. Int J Radiat Oncol Biol Phys. 2009;75:791–4.CrossRef Hodges JC, Das P, Eng C, et al. Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with Para-aortic nodal involvement. Int J Radiat Oncol Biol Phys. 2009;75:791–4.CrossRef
20.
go back to reference Dapper H, Habl G, Hirche C, et al. Dosimetric quantification of the incidental irradiation of the 'true' (deep) ano-inguinal lymphatic drainage of anal cancer patients not described in conventional contouring guidelines. Acta Oncol. 2018:1–6. Dapper H, Habl G, Hirche C, et al. Dosimetric quantification of the incidental irradiation of the 'true' (deep) ano-inguinal lymphatic drainage of anal cancer patients not described in conventional contouring guidelines. Acta Oncol. 2018:1–6.
21.
go back to reference Hirche C, Dresel S, Krempien R, Hünerbein M. Sentinel node biopsy by indocyanine green retention fluorescence detection for inguinal lymph node staging of anal cancer: preliminary experience. Ann Surg Oncol. 2010;17:2357–62.CrossRef Hirche C, Dresel S, Krempien R, Hünerbein M. Sentinel node biopsy by indocyanine green retention fluorescence detection for inguinal lymph node staging of anal cancer: preliminary experience. Ann Surg Oncol. 2010;17:2357–62.CrossRef
22.
go back to reference Schünke M, Schulte E, Schumacher U, Voll M, Wesker K. Hals und innere Organe. Stuttgart: Thieme; 2005. Schünke M, Schulte E, Schumacher U, Voll M, Wesker K. Hals und innere Organe. Stuttgart: Thieme; 2005.
23.
go back to reference Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68:794–800.CrossRef Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007;68:794–800.CrossRef
24.
go back to reference Wright JL, Patil SM, Temple LKF, Minsky BD, Saltz LB, Goodman KA. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys. 2010;78:1064–72.CrossRef Wright JL, Patil SM, Temple LKF, Minsky BD, Saltz LB, Goodman KA. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys. 2010;78:1064–72.CrossRef
25.
go back to reference Tomasoa NB, Meulendijks D, Nijkamp J, Cats A, Dewit L. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal. Acta Oncol. 2016;55:760–6.CrossRef Tomasoa NB, Meulendijks D, Nijkamp J, Cats A, Dewit L. Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal. Acta Oncol. 2016;55:760–6.CrossRef
Metadata
Title
Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines
Authors
Hendrik Dapper
Kilian Schiller
Stefan Münch
Jan C. Peeken
Kai Borm
Wolfgang Weber
Stephanie E. Combs
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5970-0

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine